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angial matrix expansion and type IV collagen accumulation inEffect of simvastatin on proliferative nephritis and cell-cycle
glomeruli. Although it might simply reflect the reduction inprotein expression.
mesangial cells, glomerular PDGF-B chain expression was re-Background. Mesangial cell proliferation is important in
duced. There was no significant difference in plasma lipidssubsequent mesangial matrix expansion in glomerular injury.
levels at day 2 and day 4. In vehicle-treated GN rats, theTherefore, the regulation of mesangial cell proliferation may
number of CDK21/OX-71 cells (CDK2-expressed mesangialbe critical in the treatment of glomerulonephritis. Inhibition of
cells) in glomeruli increased significantly from day 4 to day 7.3-hydro-3-methylglutaryl coenzyme A (HMG-CoA) reductase
Although simvastatin suppressed mesangial cell proliferation,inhibits the production of mevalonate and has been shown to
the increase in the number of glomerular CDK21/OX-71 cellssuppress proliferation in many cell types, including mesangial
was also attenuated by simvastatin treatment. There was nocells in vitro. It is expected that HMG-CoA reductase inhibitor
difference in the number of p27Kip11/OX-71 cells (p27Kip1-may suppress mesangial cell proliferation and subsequent pro-
expressed mesangial cells) in the glomerulus between vehicle-gression of glomerulonephritis. Recently, the tight relationship
treated and simvastatin-treated GN rats.between cell-cycle regulatory protein expression and mesangial
Conclusion. Simvastatin suppressed mesangial cell prolifera-cell proliferation in experimental glomerulonephritis was dem-
tion and subsequent matrix expansion, and macrophage infil-onstrated. The aim of the present study is to examine the effect
tration into glomeruli in anti-Thy 1.1 GN rats. The antiprolifer-of simvastatin, one of the HMG-CoA reductase inhibitors, on
ative effect of simvastatin in this model was also associatedthe glomerular cell proliferation and on the expression of
with the reduction of CDK2 expression in mesangial cells.CDK2 or p27Kip1 in mesangial cells in experimental glomeru-
lonephritis in vivo.
Methods. The effect of simvastatin on a rat mesangial prolif-
erative glomerulonephritis induced by antithymocyte antibody Mesangial cell proliferation and accumulation of mes-
(anti-Thy 1.1 GN) was studied. Administration of simvastatin angial extracellular matrix protein are central histologicor vehicle (for control GN) were started from two days before
feature in most of progressive glomerular diseases. Thesedisease induction, and was continued to the day of nephrec-
process may precede the development of glomeruloscle-tomy. Nephrectomy was done at days 0, 2, 4, 7, 12 and 20 after
disease induction. Immunohistochemistry for proliferating cells, rosis that is characterized by an increased amount of
macrophages, a-smooth muscle actin, type IV collagen and extracellular matrix and represents a progressive obliter-
PDGF-B chain was performed, respectively, in addition to ative process. Recent experimental studies demonstrated
conventional periodic-acid Schiff staining. Double immuno-
the important role of mesangial cell proliferation in sub-staining for CDK2/OX-7 or p27Kip1/OX-7 was also done, re-
sequent matrix protein accumulation in the glomerulus.spectively.
Therefore, understanding these mechanisms and the reg-Results. There was no difference in the degree of the initial
injuries between simvastatin-treated and control GN rats. The ulation of mesangial cell proliferation may provide useful
most pronounced feature of simvastatin-treated GN was the insights into future therapeutic strategies for human pro-
suppression of the early glomerular cell proliferation (about gressive glomerulonephritis.70% of proliferation was suppressed at day 4). At day 4,
Recently, many reports indicated the important rolea-smooth muscle actin expression was also decreased in simvas-
of mevalonate pathway in DNA replication and cell pro-tatin-treated GN rats. Inhibition of macrophage recruitment
into glomeruli by simvastatin was also a prominent feature liferation. The first step of mevalonate synthesis is the
(about 30% decrease in the number of glomerular macrophages production of 3-hydroxy-3-methylglutaryl coenzyme A
at day 2). Simvastatin significantly suppressed subsequent mes- (HMG-CoA) from acetyl coenzyme A. Mevalonate is
synthesized from HMG-CoA by HMG-CoA reductase
and many products from mevalonate, such as isoprenoidKey words: mesangial proliferative glomerulonephritis, glomerular in-
jury, progression of renal disease, anti-Thy glomerulonephritis. product, play important role in cell proliferation [1].
Therefore, inhibition of the production of mevalonate 1999 by the International Society of Nephrology
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by HMG-CoA reductase inhibitor has been shown to rats was associated with an acute complement-dependent
mesangiolysis with a loss of mesangial cells that peakedsuppress proliferation in many cell types in vitro. Several
reports about antiproliferative effect of HMG-CoA re- at 24 to 48 hours. Simvastatin-treated rats had equivalent
mesangiolysis as vehicle-treated rats at all times studiedductase inhibitor on mesangial cells have been reported.
Lovastatin inhibits proliferation of rat mesangial cells and a reduction in glomerular cell number due to mesan-
giolysis at day 2 was similar between groups (Table 1).[2] and simvastatin inhibits PDGF-induced DNA synthe-
sis in human mesangial cells in vitro [3]. Geranylgeranyl From these results, simvastatin did not alter the disease
by modulating the initial antibody and complement-pyrophosphate (GGPP) was more effective than farnesyl
pyrophosphate (FFP) in restoring lovastatin-induced in- mediated injury in anti-Thy 1.1 GN. As we have pre-
viously reported, the most pronounced feature of simvas-hibition of human mesangial cell DNA synthesis, and
therefore, GGPP may be one of the most important tatin-treated GN rat was the suppression of the early
glomerular cell proliferation [4]. The proliferative ac-molecules in human mesangial cell proliferation [1]. The
inhibition of endogenous isoprenoid products synthesis ity was maximal at day 4 after disease induction, how-
ever, about 70% of proliferation was suppressed byand the resulting suppression of their function are a
central feature in antiproliferative effects of HMG-CoA simvastatin reatment. Simvastatin administration also
decreased a-smooth muscle actin expression in the glo-reductase inhibition in cultured mesangial cells. There-
fore, specific inhibitors of isoprenoid functions may be merulus, which is a marker for mesangial cell activation,
at day 4 after disease induction (Table 1). These observa-more effective in suppressing mesangial cell prolifer-
ation [1]. tions suggest that the suppression of glomerular cell pro-
liferation in simvastatin-treated nephritis rats was mainly
due to the suppression of mesangial cell proliferation.
EFFECT OF HMG COA REDUCTASE
We also found that the PDGF expression was reduced
INHIBITORS IN MESANGIAL CELL
in simvastatin-treated nephritic rats (Table 1). Pre-
PROLIFERATION AND SUBSEQUENT
viously, we have reported that PDGF is primarily ex-MATRIX EXPANSION IN ANTI-THY 1.1
pressed by mesangial cells in this model, so the reductionNEPHRITIS IN VIVO
in expression may simply reflect the reduction in mesan-
The antiproliferative property of HMG-CoA reduc- gial cell proliferation and mesangial cellularity. This is
tase inhibitors on cultured mesangial cells raised the further suggested by the observation that lovastatin does
possibility that they may suppress mesangial cell prolifer- not block PDGF expression by mesangial cells exposed
ation and prevent the subsequent development of matrix to serum (abstract; Guijarro et al, J Am Soc Nephrol
expansion in progressive glomerular diseases in vivo, in 5:943, 1994), despite its ability to inhibit the proliferative
addition to their potential beneficial effect on glomerular response [2].
injury by lowering serum lipids, as shown previously. In anti-Thy 1.1 GN, mesangial matrix expansion due
We studied the effect of simvastatin on glomerular to extracellular matrix accumulation is maximal at day
pathology in a rat mesangial proliferative glomerulone- 7, which followed maximal glomerular cell proliferation
phritis induced by antithymocyte monoclonal antibody at day 4. Simvastatin treatment dramatically suppressed
(anti-Thy 1.1 GN) [4]. This model is characterized by mesangial matrix expansion and type IV collagen accu-
macrophage infiltration, mesangial cell proliferation, and mulation from day 4 to day 20 (Table 1), that might
subsequent mesangial matrix expansion. Although anti- be due to the inhibition of mesangial cell proliferation.
Thy 1.1 GN is not a model of progressive injury and is However, it is also possible that simvastatin could act
associated with only a mild decline in renal function, it by direct effects on mesangial matrix production. The
is thought to be the best model for studying the effect of antiproliferative effect of HMG CoA reductase inhibi-
simvastatin on glomerular cell proliferation and matrix tors has been also indicated previously [6] (abstract;
expansion. Administration of simvastatin or vehicle (for Walli et al, Circulation 90:I-233, 1994).
control GN) was started from two days before disease
induction by a single intravenous injection of antirat Thy
EFFECT OF HMG COA REDUCTASE1.1 monoclonal antibody, and was continued to the day
INHIBITORS ON MACROPHAGEof nephrectomy. Six groups of simvastatin- or vehicle-
INFILTRATION IN GLOMERULI INtreated rats were studied, respectively: rats without dis-
ANTI-THY 1.1 GNease induction (day 0); and rats with anti-Thy 1.1 GN
at two days after disease induction (day 2), at day 4, at Induction of anti-Thy 1.1 GN resulted in an early glo-
merular influx of monocytes/macrophages (maximal atday 7, at day 12 and at day 20. Another set of experiments
to document the effects of simvastatin in normal rats day 2 after disease induction), which then slowly de-
creased during the course of the disease. As we havewas performed to exclude the nonspecific toxic effects
of the drug. The injection of anti-Thy 1.1 antibody in reported previously, there was a 30% decrease in the
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Table 1. Histological results
Treatment Day 0 Day 2 Day 4 Day 7 Day 12 Day 20
Total glomerular Vehicle 69.164.3 59.0 65.7 85.2 64.0 100.766.6 83.3 65.0 77.1 62.4
cells/glom Simvastatin 70.163.8 57.1 62.9 75.5 63.4a 74.463.9a 75.963.0a 67.362.9a
PCNA-positive Vehicle 1.360.3 14.962.0 26.5 66.5 8.0 62.1 2.2 60.4 1.7 60.2
cells/glom Simvastatin 1.460.1 3.9 61.0a 8.062.7a 2.061.4a 2.460.5 1.7 60.4
Macrophages Vehicle 1.260.4 17.562.6 9.0 62.1 5.1 60.5 2.6 60.9 1.5 60.7
/glom Simvastatin 1.560.2 12.061.7a 7.863.3 2.9 61.0 2.8 60.4 2.1 60.8
a SMA Vehicle 0.160.1 0.5 60.3 3.5 60.3 3.1 60.7 2.3 60.8 0.9 60.2
staining score Simvastatin 0.160.1 0.5 60.2 2.1 60.3a 2.860.9 2.0 60.6 0.7 60.1
Mesangiolysis Vehicle 0 1.660.4 1.2 60.4 0.5 60.3 0.2 60.2 0.1 60.2
score Simvastatin 0 1.660.3 1.1 60.4 0.5 60.1 0.1 60.2 0.1 60.1
Mesangial Vehicle 0 0.360.1 1.2 60.4 2.0 60.5 1.3 60.3 0.7 60.2
matrix core Simvastatin 0 0.260.2 0.7 60.3a 0.760.3a 0.560.4a 0.260.1a
CollagenIV Vehicle 0.260.3 0.7 60.3 1.7 60.2 3.0 60.5 1.9 60.2 1.2 60.4
staining score Simvastatin 0.260.2 0.8 60.2 0.8 60.2a 2.360.3a 1.260.5b 0.460.2a
PDGF B-chain Vehicle 0.160.2 0.3 60.1 2.2 60.4 1.4 60.3 1.5 60.3 0.5 60.2
staining score Simvastatin 0.160.1 0.2 60.2 1.5 60.2a 0.760.3a 0.660.2a 0.160.2a
CDK21/OX-71 Vehicle 0.2960.01 0.23 60.1 0.92 60.12 0.68 60.06 0.19 60.06 0.21 60.03
cells/glom Simvastatin not done 0.1360.02 0.43 60.03a 0.1960.03a 0.1760.03 0.18 60.03
Abbreviations are: vehicle, vehicle-treated anti-Thy 1.1 GN rats; simvastatin, simvastatin-treated anti-Thy 1.1 GN rats.
All data were expressed as mean 6 se. A part of the table was presented in reference 4.
aP , 0.01 vs vehicle-treated rats on the same experimental day
bP , 0.05 vs vehicle-treated rats on the same experimental day
number of glomerular macrophage infiltration at day 2 land et al showed the expression of them in vivo in
after anti-Thy 1.1 GN induction by simvastatin treatment normal rats and rats with anti-Thy 1.1 GN [9]. They
(Table 1) [4]. Inhibition of monocyte/macrophage re- demonstrated that normal quiescent rat glomeruli have
cruitment into glomeruli by simvastatin was also a promi- a differential CKI expressions, such as high p27Kip1 and
nent feature in the present study. Macrophages are low p21 expression. They also showed that the onset of
thought to be important effector cells in glomerular in- mesangial cell proliferation is associated with a reduction
jury and matrix expansion. Therefore, regulation of mac- in p27Kip1 levels when mesangial cell proliferation is
rophage infiltration might lessen any subsequent glomer- maximal and is also associated with an increased glomer-
ular damage. It has already been reported that lovastatin ular expressions for cyclin A and for CDK2. Further-
reduced the glomerular macrophage infiltration in ne- more, they showed that the resolution of mesangial cell
phrotic rat induced with puromycin aminonucleoside. proliferation was associated with a return to baseline
The mechanisms by which HMG-CoA reductase inhibi- levels for p27Kip1, while p21 expression was maintained
tors block monocyte/macrophage infiltration in glomer- following the resolution of proliferation [9], they also
uli are incompletely understood, but may relate to the demonstrated that p27Kip1 safeguards against inflam-
ability of these agents to inhibit important monocyte matory glomerular injury in anti-GBM glomerulonephri-
chemokines and adhesion molecules. Massy et al have tis [10]. We studied the effect of simvastatin on CDK2
reported that the mevalonate pathway can mediate che- and p27Kip1 expression in mesangial cells in anti-Thy
mokine (MCP-1) expression in mesangial cells (abstract; 1.1 GN by double immunostaining for CDK2/OX-7 and
Massy et al, J Am Soc Nephrol 7:1859, 1996), so it is for p27Kip1/OX-7. In vehicle-treated GN rats, the num-
tempting to speculate that simvastain could be acting by ber of CDK21/OX-71 cells (CDK2-expressed mesan-
blocking MCP-1 expression. gial cell) in glomeruli increased significantly from day 4
to day 7 after disease induction. Although simvastatin
EFFECT OF HMG COA REDUCTASE suppressed mesangial cell proliferation in this model, the
INHIBITORS ON CELL-CYCLE PROTEIN increase in the number of glomerular CDK21/OX-71
EXPRESSION IN GLOMERULI IN cells was also attenuated by simvastatin treatment (Table
ANTI-THY 1.1 GN 1 and Fig. 1). p27Kip1 was observed in mesangial cells
(OX-7 positive), glomerular endothelial and epithelialCell proliferation in vitro is regulated at the level of the
cells as reported previously. There was a significant re-cell-cycle by specific cyclins and their catalytic partners,
duction in the number of p27Kip11/OX-71 cells in thecyclin dependent kinases (CDK), and the cell-cycle is
glomerulus at day 2 (1.67 6 0.47/20 glomeruli, mean 6also regulated by the cyclin kinase inhibitors (CKI) [9].
se, P , 0.01) and day 4 (4.07 6 0.59, P , 0.02), comparedAlthough the expression of cell-cycle regulatory proteins
in the kidney and in renal disease was unknown, Shank- to day 0 (9.03 6 1.10) in vehicle-treated anti-Thy 1.1 GN
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Fig. 1. Indirect immunoperoxidase double-
staining for cyclin-dependent kinase 2 (CDK2)
and OX-7. A representative glomerulus at day
4 of anti-Thy 1.1 glomerulonephritis treated
with vehicle that shows positive staining for
CDK2 in 2 nuclei (arrow), colocalized with
cells that express OX-7 (A, 3600). However,
in simvastatin-treated GN rat at day 4, there
are no positive CDK21/OX-71 cells in the
glomerulus (B, 3600).
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